1. Home
  2. ALT

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Founded: N/A Country:
United States
United States
Employees: N/A City: GAITHERSBURG
Market Cap: 519.7M IPO Year: N/A
Target Price: $17.25 AVG Volume (30 days): 4.3M
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.61 EPS Growth: N/A
52 Week Low/High: $2.09 - $14.84 Next Earning Date: 05-09-2024
Revenue: $410,000 Revenue Growth: N/A
Revenue Growth (this year): -99.21% Revenue Growth (next year): N/A

ALT Daily Stock ML Predictions

Share on Social Networks: